HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.

Abstract
Multiple myeloma (MM) characterized by proliferation of plasma cells in bone marrow and production of monoclonal immunoglobulin's. Recently, arsenic trioxide (ATO), has been considered for treatment refractory MM. We assessed the safety and efficacy of ATO for patients with refractory MM. A phase 2, study of arsenic trioxide was conducted in 12 MM patients, whose refractory to two standard therapy. Patients received arsenic trioxide, 0.25 mg/kg/d for 5 d/week during the first 2 consecutive weeks of each 4-week cycle with 2 week rest. Patients who completed one 4-week cycle were evaluated for response to treatment. Twelve patients with refractory multiple myeloma received ATO. Disease assessment was based the amount of serum proteins electrophoresis. Of the10 patients; stable disease was observed in four patients(33%), progression disease in five patients (41.6%), complete response in one patient (3.8%) and the remaining two patients could not be assessed for a response (because of increased liver enzymes after the first week). Some adverse events: increase liver enzymes and serum creatinine, neutropenia, pruritus, nausea, vomiting, lower extremities edema, noninfectious diarrhea was observed. These results indicate that ATO is active and well tolerated as a single-agent salvage therapy, even in patients with late-stage, refractory MM.
AuthorsZohreh Sanaat, Mahtab Rezazadeh, Jalial Vaez Gharamaleki, Jamal Eivazi Ziae, Ali Esfahani
JournalActa medica Iranica (Acta Med Iran) Vol. 49 Issue 8 Pg. 504-8 ( 2011) ISSN: 1735-9694 [Electronic] Iran
PMID22009804 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Arsenicals
  • Interleukin-6
  • Oxides
  • Vascular Endothelial Growth Factor A
  • arsenic trioxide
Topics
  • Adult
  • Aged
  • Arsenicals (therapeutic use)
  • Female
  • Humans
  • Interleukin-6 (blood)
  • Male
  • Middle Aged
  • Multiple Myeloma (drug therapy)
  • Oxides (therapeutic use)
  • Prospective Studies
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: